Nyannie的个人主页 - 老虎社区

Nyannie

Nyannie

暂无个人介绍

IP属地：未知

311关注

24粉丝

0主题

0勋章

2021-09-30

Good

抱歉，原内容已删除

2021-09-03

Good

抱歉，原内容已删除

2021-11-03

Good

抱歉，原内容已删除

2021-09-06

Good

抱歉，原内容已删除

2021-09-01

Good

抱歉，原内容已删除

2021-08-18

Ok

Toplines Before US Market Opens Wednesday

2021-11-07

Fokf

抱歉，原内容已删除

2021-11-01

Good

What's the best month for stocks? Hint: the next four weeks

2021-10-05

Good

抱歉，原内容已删除

2021-11-28

Good

抱歉，原内容已删除

2021-09-04

Nice

抱歉，原内容已删除

2021-08-30

Hood

抱歉，原内容已删除

2021-11-29

Good

Moderna, Pfizer, and Novavax Are Must-Own Stocks This Week

2021-11-22

Good

抱歉，原内容已删除

2021-11-04

Nice

抱歉，原内容已删除

2021-10-24

Good

抱歉，原内容已删除

2021-09-15

Good

抱歉，原内容已删除

2021-09-11

Gkkd

抱歉，原内容已删除

2021-09-02

Good

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3582719067968878","uuid":"3582719067968878","gmtCreate":1619626233994,"gmtModify":1634435628264,"name":"Nyannie","pinyin":"nyannie","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":24,"headSize":311,"tweetSize":116,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.14","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":607391289,"gmtCreate":1639485590344,"gmtModify":1639485590615,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/607391289","repostId":"1110120887","repostType":4,"repost":{"id":"1110120887","kind":"news","pubTimestamp":1639482502,"share":"https://www.laohu8.com/m/news/1110120887?lang=&edition=full","pubTime":"2021-12-14 19:48","market":"us","language":"en","title":"3M to combine food safety business with Neogen","url":"https://stock-news.laohu8.com/highlight/detail?id=1110120887","media":"Reuters","summary":"Industrial giant 3M Co(MMM.N)will separate its food safety business and merge it with Neogen Corp(NE","content":"<p>Industrial giant 3M Co(MMM.N)will separate its food safety business and merge it with Neogen Corp(NEOG.O)in a $5.3 billion deal, including new debt, the food testing and animal healthcare specialist said on Tuesday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3M to combine food safety business with Neogen</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3M to combine food safety business with Neogen\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-14 19:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/markets/deals/3m-combine-food-safety-business-with-neogen-2021-12-14/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Industrial giant 3M Co(MMM.N)will separate its food safety business and merge it with Neogen Corp(NEOG.O)in a $5.3 billion deal, including new debt, the food testing and animal healthcare specialist ...</p>\n\n<a href=\"https://www.reuters.com/markets/deals/3m-combine-food-safety-business-with-neogen-2021-12-14/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MMM":"3M"},"source_url":"https://www.reuters.com/markets/deals/3m-combine-food-safety-business-with-neogen-2021-12-14/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1110120887","content_text":"Industrial giant 3M Co(MMM.N)will separate its food safety business and merge it with Neogen Corp(NEOG.O)in a $5.3 billion deal, including new debt, the food testing and animal healthcare specialist said on Tuesday.","news_type":1,"symbols_score_info":{"MMM":0.9}},"isVote":1,"tweetType":1,"viewCount":1842,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604830655,"gmtCreate":1639366638899,"gmtModify":1639366639203,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/604830655","repostId":"1137818413","repostType":4,"repost":{"id":"1137818413","kind":"news","pubTimestamp":1639364203,"share":"https://www.laohu8.com/m/news/1137818413?lang=&edition=full","pubTime":"2021-12-13 10:56","market":"us","language":"en","title":"Amazon Stock vs. the Omicron Variant – What You Need to Know","url":"https://stock-news.laohu8.com/highlight/detail?id=1137818413","media":"TheStreet","summary":"Amazon didn’t just survive the first round of Covid lockdowns – it thrived because of them. With the","content":"<p>Amazon didn’t just survive the first round of Covid lockdowns – it thrived because of them. With the Omicron variant rattling the stock market, investors are wondering if Amazon can pull it off again.</p>\n<p>Although 2020 was a curse for brick-and-mortar businesses, it was a blessing for e-commerce. And among the most blessed of all was&nbsp;<b>Amazon</b>(<b>AMZN</b>).</p>\n<p>With billions of people around the globe stuck at home due to government-mandated lockdowns, it’s no surprise that Amazon’s sales skyrocketed last year.</p>\n<p>And it should also come as no surprise that, once lockdown restrictions eased in 2021, the Seattle-based behemoth saw its revenue growth start to slow.</p>\n<p>That was especially the case in the third quarter, when Amazon’s revenue missed both top- and bottom-line expectations.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b26230534e7279e5f9c21077e59cf721\" tg-width=\"1240\" tg-height=\"930\" width=\"100%\" height=\"auto\"><span>Figure 1: Amazon Go store in New York, NY.</span></p>\n<p>But now the Omicron variant has the world worried again. Currently, we don’t know just how dangerous this fast-spreading strain of COVID is. But the growing number of cases has people wondering if more lockdown mandates are in the works.</p>\n<p>If the world were to shut down again, would Amazon’s revenue repeat last year’s performance? Let’s take a look at what might be in store for AMZN stock.</p>\n<p><b>Would another lockdown hurt Amazon?</b></p>\n<p>Analysts agree: If the Omicron variant causes another lockdown, it’s likely we’ll see another increase in e-commerce sales.</p>\n<p>But this time, traditionally brick-and-mortar retailers have “wised up” and improved their own e-commerce efforts. Will this increase in competition sink Amazon’s profits?</p>\n<p>At this point, Amazon is so huge that even an iceberg of rivals would hardly make a dent.</p>\n<p>Other retailers have been suffering from supply-chain constraints and labor-related pressures. But Amazon has the advantages of scale. The company has also been investing in improvements to its supply-chain infrastructure to keep products on warehouse shelves.</p>\n<p>As for labor, the company has always had a high turnover rate around 150%. Amazon has had plenty of practice of finding new workers.</p>\n<p>In fact, given the company’s many advantages, it’s possible that investors could use Amazon’s stock as a hedge against another lockdown.</p>\n<p><b>Amazon is Cramer’s No. 1 pick</b></p>\n<p><i>Mad Money</i>&nbsp;host Jim Cramer&nbsp;recently announced&nbsp;that Amazon is his No. 1 stock pick if the Omicron variant causes either another round of lockdowns or a slowdown in the economy.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4c69a86e9a1e2e2f2ec78ad5128d0907\" tg-width=\"1240\" tg-height=\"827\" width=\"100%\" height=\"auto\"><span>Figure 2: Mad Money's host Jim Cramer.</span></p>\n<p>He argued that – in addition to Amazon’s e-commerce business – its Amazon Web Services (AWS) segment sets it apart from the rest.</p>\n<p>According to Cramer, no matter what happens with the Omicron variant or the economy, businesses will still migrate to cloud computing. And so far, AWS is the market leader by a wide margin.</p>\n<blockquote>\n “[Amazon] is a company that does well when people are scared to go to the mall. And it does well as more companies embrace the cloud, because Amazon Web Services is indeed the dominant player in cloud infrastructure,” he noted.\n</blockquote>\n<p>In addition, he noted that, when the going gets tough, Amazon can always get away with raising its prices.</p>\n<p><b>Our take</b></p>\n<p>Although we don’t know for certain what effects the Omicron strain will ultimately have on the global economy, it has already caused some extra volatility in the markets.</p>\n<p>For investors, Amazon’s stock might work well as a hedge against another lockdown. After all, its business segments – including e-commerce and cloud computing – have already benefited from such a scenario. Why not do it again?</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon Stock vs. the Omicron Variant – What You Need to Know</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon Stock vs. the Omicron Variant – What You Need to Know\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 10:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/amazon/news/amazon-stock-vs-the-omicron-variant-what-you-need-to-know><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amazon didn’t just survive the first round of Covid lockdowns – it thrived because of them. With the Omicron variant rattling the stock market, investors are wondering if Amazon can pull it off again....</p>\n\n<a href=\"https://www.thestreet.com/amazon/news/amazon-stock-vs-the-omicron-variant-what-you-need-to-know\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊"},"source_url":"https://www.thestreet.com/amazon/news/amazon-stock-vs-the-omicron-variant-what-you-need-to-know","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137818413","content_text":"Amazon didn’t just survive the first round of Covid lockdowns – it thrived because of them. With the Omicron variant rattling the stock market, investors are wondering if Amazon can pull it off again.\nAlthough 2020 was a curse for brick-and-mortar businesses, it was a blessing for e-commerce. And among the most blessed of all was Amazon(AMZN).\nWith billions of people around the globe stuck at home due to government-mandated lockdowns, it’s no surprise that Amazon’s sales skyrocketed last year.\nAnd it should also come as no surprise that, once lockdown restrictions eased in 2021, the Seattle-based behemoth saw its revenue growth start to slow.\nThat was especially the case in the third quarter, when Amazon’s revenue missed both top- and bottom-line expectations.\nFigure 1: Amazon Go store in New York, NY.\nBut now the Omicron variant has the world worried again. Currently, we don’t know just how dangerous this fast-spreading strain of COVID is. But the growing number of cases has people wondering if more lockdown mandates are in the works.\nIf the world were to shut down again, would Amazon’s revenue repeat last year’s performance? Let’s take a look at what might be in store for AMZN stock.\nWould another lockdown hurt Amazon?\nAnalysts agree: If the Omicron variant causes another lockdown, it’s likely we’ll see another increase in e-commerce sales.\nBut this time, traditionally brick-and-mortar retailers have “wised up” and improved their own e-commerce efforts. Will this increase in competition sink Amazon’s profits?\nAt this point, Amazon is so huge that even an iceberg of rivals would hardly make a dent.\nOther retailers have been suffering from supply-chain constraints and labor-related pressures. But Amazon has the advantages of scale. The company has also been investing in improvements to its supply-chain infrastructure to keep products on warehouse shelves.\nAs for labor, the company has always had a high turnover rate around 150%. Amazon has had plenty of practice of finding new workers.\nIn fact, given the company’s many advantages, it’s possible that investors could use Amazon’s stock as a hedge against another lockdown.\nAmazon is Cramer’s No. 1 pick\nMad Money host Jim Cramer recently announced that Amazon is his No. 1 stock pick if the Omicron variant causes either another round of lockdowns or a slowdown in the economy.\nFigure 2: Mad Money's host Jim Cramer.\nHe argued that – in addition to Amazon’s e-commerce business – its Amazon Web Services (AWS) segment sets it apart from the rest.\nAccording to Cramer, no matter what happens with the Omicron variant or the economy, businesses will still migrate to cloud computing. And so far, AWS is the market leader by a wide margin.\n\n “[Amazon] is a company that does well when people are scared to go to the mall. And it does well as more companies embrace the cloud, because Amazon Web Services is indeed the dominant player in cloud infrastructure,” he noted.\n\nIn addition, he noted that, when the going gets tough, Amazon can always get away with raising its prices.\nOur take\nAlthough we don’t know for certain what effects the Omicron strain will ultimately have on the global economy, it has already caused some extra volatility in the markets.\nFor investors, Amazon’s stock might work well as a hedge against another lockdown. After all, its business segments – including e-commerce and cloud computing – have already benefited from such a scenario. Why not do it again?","news_type":1,"symbols_score_info":{"AMZN":0.9}},"isVote":1,"tweetType":1,"viewCount":2175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605596343,"gmtCreate":1639187445275,"gmtModify":1639187445530,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605596343","repostId":"2190673267","repostType":4,"isVote":1,"tweetType":1,"viewCount":2041,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605134376,"gmtCreate":1639127509897,"gmtModify":1639127823038,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Vgg","listText":"Vgg","text":"Vgg","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605134376","repostId":"1116553400","repostType":4,"isVote":1,"tweetType":1,"viewCount":2484,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606673970,"gmtCreate":1638878391460,"gmtModify":1638878391674,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/606673970","repostId":"1102192068","repostType":4,"isVote":1,"tweetType":1,"viewCount":2159,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608861237,"gmtCreate":1638683088038,"gmtModify":1638683088195,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/608861237","repostId":"2188578706","repostType":4,"isVote":1,"tweetType":1,"viewCount":2239,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601170693,"gmtCreate":1638502178933,"gmtModify":1638502179055,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/601170693","repostId":"1108760971","repostType":4,"repost":{"id":"1108760971","kind":"news","pubTimestamp":1638499412,"share":"https://www.laohu8.com/m/news/1108760971?lang=&edition=full","pubTime":"2021-12-03 10:43","market":"us","language":"en","title":"Grab SPAC Merger Alert: 8 Things to Know as GRAB Stock Falls 20% on Its Nasdaq Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=1108760971","media":"InvestorPlace","summary":"Southeast Asia ride-hailing and food-delivery company Grab(NASDAQ:GRAB) went public today to a fairl","content":"<div>\n<p>Southeast Asia ride-hailing and food-delivery company Grab(NASDAQ:GRAB) went public today to a fairly muted reaction from investors. The Singapore-based company first piqued investors’ attention with ...</p>\n\n<a href=\"https://investorplace.com/2021/12/grab-spac-merger-alert-8-things-to-know-as-grab-stock-falls-20-on-its-nasdaq-debut/\">Web Link</a>\n\n</div>\n","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grab SPAC Merger Alert: 8 Things to Know as GRAB Stock Falls 20% on Its Nasdaq Debut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrab SPAC Merger Alert: 8 Things to Know as GRAB Stock Falls 20% on Its Nasdaq Debut\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-03 10:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/grab-spac-merger-alert-8-things-to-know-as-grab-stock-falls-20-on-its-nasdaq-debut/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Southeast Asia ride-hailing and food-delivery company Grab(NASDAQ:GRAB) went public today to a fairly muted reaction from investors. The Singapore-based company first piqued investors’ attention with ...</p>\n\n<a href=\"https://investorplace.com/2021/12/grab-spac-merger-alert-8-things-to-know-as-grab-stock-falls-20-on-its-nasdaq-debut/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GRAB":"Grab Holdings"},"source_url":"https://investorplace.com/2021/12/grab-spac-merger-alert-8-things-to-know-as-grab-stock-falls-20-on-its-nasdaq-debut/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108760971","content_text":"Southeast Asia ride-hailing and food-delivery company Grab(NASDAQ:GRAB) went public today to a fairly muted reaction from investors. The Singapore-based company first piqued investors’ attention with its array of super apps across financial, delivery and transportation services. Despite opening at $12.40 this morning, GRAB stock has steadily declined, currently sitting at $8.75 at market close, more than 20% down on the day.\nGrab is one of many highly anticipated companies that have gone public via special purpose acquisition company (SPAC) mergers. Indeed, it’s been a packed field for SPAC mergers this season. More and more companies opt to go public via SPAC nowadays, as it has the potential to save tremendous amounts of time and money in their initial public offerings (IPOs). Not every company thrives off of it, however, as is evident this afternoon.\nGrab Chief Executive Anthony Tan commented onGRAB’s downtrend today. “The price makes no difference to me. I’m going to celebrate tonight and get back to work tomorrow,” Tan said.\nSo, what else should investors know about GRAB stock today?\n8 Things to Know as GRAB Stock Slides Today\n\nGRAB’s backdoor listing comes after an agreement with U.S. tech SPAC, Altimeter Growth Corp.\nThe deal saw GRAB raise $4.5 billion in funding, including $750 million from Altimeter.\nGrab is a high-growth contender. Some expect the Southeast Asia digital economy to double by 2025.\nThe company began as a Malaysia-based taxi app in 2012. Since then, it’s expanded into various other industries and mobile services.\nAdditionally, GRAB has support from some big players. Indeed, Toyota(NYSE:TM), Microsoft(NASDAQ:MSFT) and Uber(NYSE:UBER) each have a stake in the company.\nUnfortunately, Grab had less-than stellar revenue numbers to report this past quarter. Revenue was down 9% year-over-year, mostly attributed to Covid-19-related lockdowns across Southeast Asia, especially Vietnam.\nHowever, Grab is aiming for profitability by 2023. At that point, the burgeoning Southeast Asian internet economy is expected to have grown substantially.\nThe super apps are operational in more than 465 cities across eight countries and offer everything from food-delivery to investment services.","news_type":1,"symbols_score_info":{"GRAB":0.9}},"isVote":1,"tweetType":1,"viewCount":3862,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609392913,"gmtCreate":1638236931520,"gmtModify":1638237337163,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/609392913","repostId":"1105270576","repostType":4,"repost":{"id":"1105270576","kind":"news","pubTimestamp":1638236121,"share":"https://www.laohu8.com/m/news/1105270576?lang=&edition=full","pubTime":"2021-11-30 09:35","market":"us","language":"en","title":"Wall Street Dip Buyers Defy Omicron Inflation Risk at Their Own Peril","url":"https://stock-news.laohu8.com/highlight/detail?id=1105270576","media":"Bloomberg","summary":"(Bloomberg) -- If there’s any lesson for Wall Street in the pandemic era, it’s this: Every selloff h","content":"<p>(Bloomberg) -- If there’s any lesson for Wall Street in the pandemic era, it’s this: Every selloff has proved a big opportunity to buy the dip in a world of activist central banks and limitless risk appetite.</p>\n<p>Yet the Monday rally as the omicron variant spreads will test the resolve of investors who thought they’d seen it all in the Covid roller coaster.</p>\n<p>With fresh travel bans looming and transmission fears rife, the S&amp;P 500 rallied more than 1% at the open after the index’s worst drop in nine months Friday. Treasuries slumped, sending yields higher, while oil jumped.</p>\n<p>To the likes of Goldman Sachs Group Inc. and UBS Wealth Management, it all makes sense -- they reckon bad virus news has some good news for markets as the variant assuages fears of monetary tightening. But strategists at Capital Economics and Mizuho International are among those urging caution as rising cases may worsen inflation, keeping policy makers on track to cut stimulus.</p>\n<p>“I know, I know, ‘U.S. equities only go up’ etc,” wrote Peter Chatwell, head of multi-asset strategy at Mizuho. “Monetary tightening is a structural downside risk to equities, and it may coincide with weaker growth in Q1.”</p>\n<p>While mild omicron symptoms and news of rapid vaccine reformulations are offering some relief Monday, European policy makers were already tightening rules to fight another wave of infections even before the mutation was discovered in southern Africa late last week.</p>\n<p>The sharp risk-off session Friday, exacerbated by thin liquidity after the Thanksgiving holiday, was a sign of investors’ sensitivity to any bad headlines, with their pockets already thickly lined from the S&amp;P 500’s 24% gain this year.</p>\n<p>While corporations have managed to deliver a sharp profit recovery in 2021, stock valuations are elevated historically: The U.S. benchmark is trading at 21 times the next year’s earnings, compared with 18 at the end of 2019 and a decade average of close to 17.</p>\n<p>Whether that multiple counts as stretched will largely depend on the monetary trajectory. And since omicron hit the headlines, money-market traders have pushed back expectations for global rate hikes, market-derived inflation expectations have fallen and oil has plunged.</p>\n<p>All that is a sign markets are pricing in a drop in demand from the new variant, which may prompt central banks to slow their tightening.</p>\n<p>“Ironically, it may be the omicron scare itself that now creates the best possibility of some relief over the period, either because incoming news about the variant is better than feared or because monetary policy makers take a somewhat more cautious stance in response to the news,” wrote Dominic Wilson at Goldman.</p>\n<p>At UBS’s wealth-management unit, a team led by chief investment officer Mark Haefele is telling clients to stay invested with the base case of robust economic growth intact and any concerns only likely to reduce monetary-tightening fears. At Nordea Investment Funds, senior macro strategist Sebastien Galy calls it a buying opportunity.</p>\n<p>After a spike in volatility like the VIX’s 10-point jump Friday, stocks usually stage “robust reversals,” writes Jonathan Golub, chief U.S. equity strategist at Credit Suisse, in a Monday note.</p>\n<p>Yet the policy response function may be less clear-cut than it was in the first all-hands-on-deck phase of the pandemic. Last year’s experience underscored the risk that if consumers shift their spending toward goods amid supply-chain bottlenecks, renewed virus anxieties can actually be inflationary.</p>\n<p>New infections may also temporarily shrink the labor force, suggests Neil Shearing, chief economist at Capital Economics.</p>\n<p>“Compared to previous waves of the virus, which were on balance disinflationary, a major new wave could now be inflationary,” he wrote in a note. “All of this further complicates an already-complex policy challenge.”</p>\n<p>It’s a big shift from a week ago, when investors were largely preoccupied with the rate outlook based on the pace of the U.S. recovery. An index for economic surprises only this month returned to positive territory, as payrolls and retail sales expanded faster than expected.</p>\n<p>But for investors giddy after the 66 record highs notched by the S&amp;P 500 this year, an intensifying Covid risk is hard to ignore.</p>\n<p>“I am not too positive on the situation as the cause of the selloff was the new variant, but it is also worth considering that the number of infections levels in Europe were unfortunately increasing anyway,” said Alberto Tocchio, a portfolio manager at Kairos Partners. “We will need more data before we will be able to judge.”</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street Dip Buyers Defy Omicron Inflation Risk at Their Own Peril</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street Dip Buyers Defy Omicron Inflation Risk at Their Own Peril\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 09:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/wall-street-dip-buyers-defy-135337950.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- If there’s any lesson for Wall Street in the pandemic era, it’s this: Every selloff has proved a big opportunity to buy the dip in a world of activist central banks and limitless risk ...</p>\n\n<a href=\"https://finance.yahoo.com/news/wall-street-dip-buyers-defy-135337950.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯"},"source_url":"https://finance.yahoo.com/news/wall-street-dip-buyers-defy-135337950.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105270576","content_text":"(Bloomberg) -- If there’s any lesson for Wall Street in the pandemic era, it’s this: Every selloff has proved a big opportunity to buy the dip in a world of activist central banks and limitless risk appetite.\nYet the Monday rally as the omicron variant spreads will test the resolve of investors who thought they’d seen it all in the Covid roller coaster.\nWith fresh travel bans looming and transmission fears rife, the S&P 500 rallied more than 1% at the open after the index’s worst drop in nine months Friday. Treasuries slumped, sending yields higher, while oil jumped.\nTo the likes of Goldman Sachs Group Inc. and UBS Wealth Management, it all makes sense -- they reckon bad virus news has some good news for markets as the variant assuages fears of monetary tightening. But strategists at Capital Economics and Mizuho International are among those urging caution as rising cases may worsen inflation, keeping policy makers on track to cut stimulus.\n“I know, I know, ‘U.S. equities only go up’ etc,” wrote Peter Chatwell, head of multi-asset strategy at Mizuho. “Monetary tightening is a structural downside risk to equities, and it may coincide with weaker growth in Q1.”\nWhile mild omicron symptoms and news of rapid vaccine reformulations are offering some relief Monday, European policy makers were already tightening rules to fight another wave of infections even before the mutation was discovered in southern Africa late last week.\nThe sharp risk-off session Friday, exacerbated by thin liquidity after the Thanksgiving holiday, was a sign of investors’ sensitivity to any bad headlines, with their pockets already thickly lined from the S&P 500’s 24% gain this year.\nWhile corporations have managed to deliver a sharp profit recovery in 2021, stock valuations are elevated historically: The U.S. benchmark is trading at 21 times the next year’s earnings, compared with 18 at the end of 2019 and a decade average of close to 17.\nWhether that multiple counts as stretched will largely depend on the monetary trajectory. And since omicron hit the headlines, money-market traders have pushed back expectations for global rate hikes, market-derived inflation expectations have fallen and oil has plunged.\nAll that is a sign markets are pricing in a drop in demand from the new variant, which may prompt central banks to slow their tightening.\n“Ironically, it may be the omicron scare itself that now creates the best possibility of some relief over the period, either because incoming news about the variant is better than feared or because monetary policy makers take a somewhat more cautious stance in response to the news,” wrote Dominic Wilson at Goldman.\nAt UBS’s wealth-management unit, a team led by chief investment officer Mark Haefele is telling clients to stay invested with the base case of robust economic growth intact and any concerns only likely to reduce monetary-tightening fears. At Nordea Investment Funds, senior macro strategist Sebastien Galy calls it a buying opportunity.\nAfter a spike in volatility like the VIX’s 10-point jump Friday, stocks usually stage “robust reversals,” writes Jonathan Golub, chief U.S. equity strategist at Credit Suisse, in a Monday note.\nYet the policy response function may be less clear-cut than it was in the first all-hands-on-deck phase of the pandemic. Last year’s experience underscored the risk that if consumers shift their spending toward goods amid supply-chain bottlenecks, renewed virus anxieties can actually be inflationary.\nNew infections may also temporarily shrink the labor force, suggests Neil Shearing, chief economist at Capital Economics.\n“Compared to previous waves of the virus, which were on balance disinflationary, a major new wave could now be inflationary,” he wrote in a note. “All of this further complicates an already-complex policy challenge.”\nIt’s a big shift from a week ago, when investors were largely preoccupied with the rate outlook based on the pace of the U.S. recovery. An index for economic surprises only this month returned to positive territory, as payrolls and retail sales expanded faster than expected.\nBut for investors giddy after the 66 record highs notched by the S&P 500 this year, an intensifying Covid risk is hard to ignore.\n“I am not too positive on the situation as the cause of the selloff was the new variant, but it is also worth considering that the number of infections levels in Europe were unfortunately increasing anyway,” said Alberto Tocchio, a portfolio manager at Kairos Partners. “We will need more data before we will be able to judge.”","news_type":1,"symbols_score_info":{".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":1970,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600234330,"gmtCreate":1638155494839,"gmtModify":1638155494989,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/600234330","repostId":"1119853738","repostType":4,"repost":{"id":"1119853738","kind":"news","pubTimestamp":1638153494,"share":"https://www.laohu8.com/m/news/1119853738?lang=&edition=full","pubTime":"2021-11-29 10:38","market":"us","language":"en","title":"Moderna, Pfizer, and Novavax Are Must-Own Stocks This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1119853738","media":"Motley Fool","summary":"The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday","content":"<p>The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday. Omicron has the world on edge because of its unique combination of mutations that might significantly reduce the effectiveness of first-generation COVID-19 vaccines.</p>\n<p>While there simply isn't enough data to draw any firm conclusions about the seriousness of the omicron variant yet, politicians across the world were quick to react by imposing travel bans and restrictions on several African nations over the weekend. These rapid-fire travel restrictions make it abundantly clear that the global pandemic -- and its effects on the world economy -- are far from over.</p>\n<p>How should investors protect their portfolios from this latest threat to global supply chains, international travel, and public health? The answer appears to be simple enough: vaccine stocks. On Black Friday, shares of the top COVID-19 vaccine developers&nbsp;<b>Moderna</b>(NASDAQ:MRNA),<b>Pfizer</b>(NYSE:PFE), and&nbsp;<b>Novavax</b>(NASDAQ:NVAX)&nbsp;all&nbsp;vaulted higher. Here's why these threebiopharmaceutical stocksought to continue to their march northward next week and beyond.</p>\n<p>The pandemic's latest twist makes these three stocks screaming buys</p>\n<p>Moderna, Pfizer, and Novavax all enjoyed a sizable jump in their share prices during the holiday-shortened trading session on Friday thanks to their quick reaction to the omicron variant. Specifically, Moderna announced that it is working on an omicron-specific vaccine, as well a unique booster shot regimen, based on its currently authorized COVID-19 vaccine, that may provide a higher level of immune protection against this new variant.</p>\n<p>Pfizer, for its part, said that its&nbsp;<b>BioNTech</b>-partnered COVID-19 vaccine can easily be tailored to the omicron variant and be ready for use within 100-days -- that is, if the original version of its vaccine fails to provide adequate protection. Novavax also provided an update on its omicron vaccine strategy last Friday, with the biotech saying that it plans on having an omicron-specific shot ready for testing and manufacturing within the next few weeks.</p>\n<p>Why are these omicron-tailored vaccines a huge positive for their developers? The messenger RNA (mRNA) vaccines from Moderna and Pfizer/BioNTech both appeared to be on the back end of the commercial shelf lives prior to this news. As a result, Moderna's stock was in the midst of notable downward trend earlier this month. The sudden need for more potent booster shots and a potential variant-specific vaccine should keep Moderna's top line headed in the right direction in 2022, which ought to light a fire underneath the biotech's shares for the remainder of the year.</p>\n<p>While Pfizer's equity hasn't skipped a beat of late because of its oral coronavirus pill, the pharma giant now stands to possibly benefit from another year of exceptionally strong COVID-19 vaccine sales. Pfizer's stock, in turn, will probably continue to print ever-increasing record highs heading into 2022.</p>\n<p>On the Novavax side of ledger, the biotech's shares are currently down by a whopping 31% from their 52-week highs. The vaccine specialist's shares have&nbsp;dipped in the back half of 2021&nbsp;in response to manufacturing issues, regulatory delays, and a growing concern among investors that the company may have simply missed the boat.</p>\n<p>What's important to understand is that Novavax's COVID-19 vaccine is protein-based, which may appeal to a broad range of folks hesitant about cutting-edge mRNA vaccines. This new variant, therefore, ought to keep this latent demand for Novavax's alternative jab on the high side, as the company slowly completes the regulatory process in the all-important U.S. market.</p>\n<p>In short, Moderna, Pfizer, and Novavax are all poised to benefit in a big way from their unique vaccine development capabilities, making their stocks exceedingly strong buys this week.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, Pfizer, and Novavax Are Must-Own Stocks This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, Pfizer, and Novavax Are Must-Own Stocks This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-29 10:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/28/moderna-pfizer-and-novavax-are-must-own-stocks-thi/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday. Omicron has the world on edge because of its unique combination of mutations that might ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/28/moderna-pfizer-and-novavax-are-must-own-stocks-thi/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/11/28/moderna-pfizer-and-novavax-are-must-own-stocks-thi/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119853738","content_text":"The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday. Omicron has the world on edge because of its unique combination of mutations that might significantly reduce the effectiveness of first-generation COVID-19 vaccines.\nWhile there simply isn't enough data to draw any firm conclusions about the seriousness of the omicron variant yet, politicians across the world were quick to react by imposing travel bans and restrictions on several African nations over the weekend. These rapid-fire travel restrictions make it abundantly clear that the global pandemic -- and its effects on the world economy -- are far from over.\nHow should investors protect their portfolios from this latest threat to global supply chains, international travel, and public health? The answer appears to be simple enough: vaccine stocks. On Black Friday, shares of the top COVID-19 vaccine developers Moderna(NASDAQ:MRNA),Pfizer(NYSE:PFE), and Novavax(NASDAQ:NVAX) all vaulted higher. Here's why these threebiopharmaceutical stocksought to continue to their march northward next week and beyond.\nThe pandemic's latest twist makes these three stocks screaming buys\nModerna, Pfizer, and Novavax all enjoyed a sizable jump in their share prices during the holiday-shortened trading session on Friday thanks to their quick reaction to the omicron variant. Specifically, Moderna announced that it is working on an omicron-specific vaccine, as well a unique booster shot regimen, based on its currently authorized COVID-19 vaccine, that may provide a higher level of immune protection against this new variant.\nPfizer, for its part, said that its BioNTech-partnered COVID-19 vaccine can easily be tailored to the omicron variant and be ready for use within 100-days -- that is, if the original version of its vaccine fails to provide adequate protection. Novavax also provided an update on its omicron vaccine strategy last Friday, with the biotech saying that it plans on having an omicron-specific shot ready for testing and manufacturing within the next few weeks.\nWhy are these omicron-tailored vaccines a huge positive for their developers? The messenger RNA (mRNA) vaccines from Moderna and Pfizer/BioNTech both appeared to be on the back end of the commercial shelf lives prior to this news. As a result, Moderna's stock was in the midst of notable downward trend earlier this month. The sudden need for more potent booster shots and a potential variant-specific vaccine should keep Moderna's top line headed in the right direction in 2022, which ought to light a fire underneath the biotech's shares for the remainder of the year.\nWhile Pfizer's equity hasn't skipped a beat of late because of its oral coronavirus pill, the pharma giant now stands to possibly benefit from another year of exceptionally strong COVID-19 vaccine sales. Pfizer's stock, in turn, will probably continue to print ever-increasing record highs heading into 2022.\nOn the Novavax side of ledger, the biotech's shares are currently down by a whopping 31% from their 52-week highs. The vaccine specialist's shares have dipped in the back half of 2021 in response to manufacturing issues, regulatory delays, and a growing concern among investors that the company may have simply missed the boat.\nWhat's important to understand is that Novavax's COVID-19 vaccine is protein-based, which may appeal to a broad range of folks hesitant about cutting-edge mRNA vaccines. This new variant, therefore, ought to keep this latent demand for Novavax's alternative jab on the high side, as the company slowly completes the regulatory process in the all-important U.S. market.\nIn short, Moderna, Pfizer, and Novavax are all poised to benefit in a big way from their unique vaccine development capabilities, making their stocks exceedingly strong buys this week.","news_type":1,"symbols_score_info":{"MRNA":0.9,"NVAX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2088,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600311170,"gmtCreate":1638066328792,"gmtModify":1638066328908,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/600311170","repostId":"2186282013","repostType":4,"isVote":1,"tweetType":1,"viewCount":2185,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877795262,"gmtCreate":1637980592492,"gmtModify":1637980592681,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/877795262","repostId":"1128119268","repostType":4,"repost":{"id":"1128119268","kind":"news","pubTimestamp":1637972590,"share":"https://www.laohu8.com/m/news/1128119268?lang=&edition=full","pubTime":"2021-11-27 08:23","market":"us","language":"en","title":"These 3 Stocks Punished the Dow Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=1128119268","media":"Motley Fool","summary":"The stock market was definitely not in a holiday mood on the day after Thanksgiving, as news of the ","content":"<p>The stock market was definitely not in a holiday mood on the day after Thanksgiving, as news of the new Omicron variant of COVID-19 led to widespread concerns about a possible return to lockdown conditions. By the end of the day, the&nbsp;<b>Dow Jones Industrial Average</b>(DJINDICES:^DJI),<b>S&amp;P 500</b>(SNPINDEX:^GSPC), and&nbsp;<b>Nasdaq Composite</b>(NASDAQINDEX:^IXIC)were all down between 2% and 3%.</p>\n<p>Today's news hurt stocks in many different sectors of the market, with a wide variety of factors playing into losses. Because of theDow's price-weighted nature, a few stocks had a disproportionate influence on the average's moves. Below, we'll look at how&nbsp;<b>American Express</b>(NYSE:AXP),<b>Boeing</b>(NYSE:BA), and&nbsp;<b>Goldman Sachs</b>(NYSE:GS)combined to lop about 250 points off the Dow by themselves.</p>\n<p>A double hit for American Express</p>\n<p>American Express was the worst performer in the Dow, falling almost 9%. The financial company saw its stock fall for two different reasons related to the news about the pandemic.</p>\n<p>First and foremost, American Express has historically relied on global travel to drive a substantial part of its business. Its traveler's checks are known around the world as a means of doing business, and its charge cards have prestige in key market destinations. The prospects for further restrictions on travel, therefore, would have a detrimental impact on its business.</p>\n<p>Moreover, as a financial institution,American Express benefits from a steeper yield curve. The recent trend in that direction met an abrupt reversal on Friday, as bond yields plunged on prospects for a possible economic slowdown. Investors anticipate that the company could have problems meeting its own expectations if the pandemic worsens, and that's why the stock cost the Dow about 100 points on Friday.</p>\n<p>Flying lower</p>\n<p>Another company that one would've expected to fare poorly given the news was&nbsp;<b>Boeing</b>(NYSE:BA). The aerospace company fell more than 5%, and its higher-priced shares gave it a big impact on the Dow.</p>\n<p>You won't find&nbsp;airline stocks&nbsp;in the Dow Industrials, but they took even larger hits as a result of the COVID news. Already, the U.S. and other nations have put travel restrictions on South Africa and neighboring countries to try to stem the spread of the Omicron variant. That bodes poorly for airlines serving those markets, and it indirectly affects Boeing by raising the possibility that airlines will have to cancel or postpone orders if they come under additional economic pressure.</p>\n<p>Boeing has suffered substantial losses, but investors were starting to hope that it would turn profitable again in 2022. The latest news threatens that assessment, and investors don't like the prospects for more red ink from the aircraft manufacturer.</p>\n<p>Banking on rate rises</p>\n<p>Goldman Sachs was down 2.5% on Friday. Its nearly $10 decline cost the Dow roughly 70 points on the day.</p>\n<p>Goldman faced some of the same challenges that American Express does. Increasingly,Goldman has tried to boost its retail banking presence&nbsp;through its Marcus unit, and that has exposed the Wall Street financial giant to greater interest rate sensitivity. The flattening yield curve Friday didn't do any favors to the company's consumer banking segment.</p>\n<p>Wall Street has also benefited from huge levels of investment banking activity, where Goldman excels. If a market pullback leads to reduced activity for initial public offerings, acquisitions, and other corporate events, then it could hurt that part of Goldman's business as well.</p>\n<p>Don't panic</p>\n<p>A 900-point plunge for the Dow makes for a scary headline, but it's just part of the natural volatility of the stock market. Don't lose perspective, and if you stick with your long-term investment strategy, things will likely go better for you than if you panic.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These 3 Stocks Punished the Dow Friday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese 3 Stocks Punished the Dow Friday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-27 08:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/26/these-3-stocks-punished-the-dow-friday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market was definitely not in a holiday mood on the day after Thanksgiving, as news of the new Omicron variant of COVID-19 led to widespread concerns about a possible return to lockdown ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/26/these-3-stocks-punished-the-dow-friday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GS":"高盛","BA":"波音","AXP":"美国运通"},"source_url":"https://www.fool.com/investing/2021/11/26/these-3-stocks-punished-the-dow-friday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128119268","content_text":"The stock market was definitely not in a holiday mood on the day after Thanksgiving, as news of the new Omicron variant of COVID-19 led to widespread concerns about a possible return to lockdown conditions. By the end of the day, the Dow Jones Industrial Average(DJINDICES:^DJI),S&P 500(SNPINDEX:^GSPC), and Nasdaq Composite(NASDAQINDEX:^IXIC)were all down between 2% and 3%.\nToday's news hurt stocks in many different sectors of the market, with a wide variety of factors playing into losses. Because of theDow's price-weighted nature, a few stocks had a disproportionate influence on the average's moves. Below, we'll look at how American Express(NYSE:AXP),Boeing(NYSE:BA), and Goldman Sachs(NYSE:GS)combined to lop about 250 points off the Dow by themselves.\nA double hit for American Express\nAmerican Express was the worst performer in the Dow, falling almost 9%. The financial company saw its stock fall for two different reasons related to the news about the pandemic.\nFirst and foremost, American Express has historically relied on global travel to drive a substantial part of its business. Its traveler's checks are known around the world as a means of doing business, and its charge cards have prestige in key market destinations. The prospects for further restrictions on travel, therefore, would have a detrimental impact on its business.\nMoreover, as a financial institution,American Express benefits from a steeper yield curve. The recent trend in that direction met an abrupt reversal on Friday, as bond yields plunged on prospects for a possible economic slowdown. Investors anticipate that the company could have problems meeting its own expectations if the pandemic worsens, and that's why the stock cost the Dow about 100 points on Friday.\nFlying lower\nAnother company that one would've expected to fare poorly given the news was Boeing(NYSE:BA). The aerospace company fell more than 5%, and its higher-priced shares gave it a big impact on the Dow.\nYou won't find airline stocks in the Dow Industrials, but they took even larger hits as a result of the COVID news. Already, the U.S. and other nations have put travel restrictions on South Africa and neighboring countries to try to stem the spread of the Omicron variant. That bodes poorly for airlines serving those markets, and it indirectly affects Boeing by raising the possibility that airlines will have to cancel or postpone orders if they come under additional economic pressure.\nBoeing has suffered substantial losses, but investors were starting to hope that it would turn profitable again in 2022. The latest news threatens that assessment, and investors don't like the prospects for more red ink from the aircraft manufacturer.\nBanking on rate rises\nGoldman Sachs was down 2.5% on Friday. Its nearly $10 decline cost the Dow roughly 70 points on the day.\nGoldman faced some of the same challenges that American Express does. Increasingly,Goldman has tried to boost its retail banking presence through its Marcus unit, and that has exposed the Wall Street financial giant to greater interest rate sensitivity. The flattening yield curve Friday didn't do any favors to the company's consumer banking segment.\nWall Street has also benefited from huge levels of investment banking activity, where Goldman excels. If a market pullback leads to reduced activity for initial public offerings, acquisitions, and other corporate events, then it could hurt that part of Goldman's business as well.\nDon't panic\nA 900-point plunge for the Dow makes for a scary headline, but it's just part of the natural volatility of the stock market. Don't lose perspective, and if you stick with your long-term investment strategy, things will likely go better for you than if you panic.","news_type":1,"symbols_score_info":{"AXP":0.9,"BA":0.9,"GS":0.9}},"isVote":1,"tweetType":1,"viewCount":737,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877316779,"gmtCreate":1637887845784,"gmtModify":1637887845898,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/877316779","repostId":"2186395841","repostType":4,"isVote":1,"tweetType":1,"viewCount":682,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874528240,"gmtCreate":1637803334110,"gmtModify":1637803334227,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/874528240","repostId":"1176842797","repostType":4,"repost":{"id":"1176842797","kind":"news","pubTimestamp":1637801959,"share":"https://www.laohu8.com/m/news/1176842797?lang=&edition=full","pubTime":"2021-11-25 08:59","market":"us","language":"en","title":"Amazon 'Well-Positioned' Going into the Holidays, JPMorgan Says","url":"https://stock-news.laohu8.com/highlight/detail?id=1176842797","media":"TheStreet","summary":"Amazon should surpass Walmart as the largest U.S. retailer in 2022, a JPMorgan analyst says.\nAmazon ","content":"<p>Amazon should surpass Walmart as the largest U.S. retailer in 2022, a JPMorgan analyst says.</p>\n<p>Amazon&nbsp;is well-positioned going into the holidays, a JPMorgan analyst said Wednesday, and should surpass Walmart&nbsp;as the largest U.S. retailer in 2022.</p>\n<p>Analyst Doug Anmuth said in a research report he continues to expect a strong online holiday season, \"albeit against tougher comps and with a resurgence in physical retail.\"</p>\n<p>\"Amazon is well-positioned, having doubled its fulfillment network over the past 2 years, and should remain about 40% of US e-comm spend,\" Anmuth said. \"Amazon remains our top overall idea.\"</p>\n<p>The analyst said he believes Amazon will surpass Walmart as the largest U.S. retailer in 2022.</p>\n<p>\"Amazon started offering Black Friday deals on 10/4, the earliest start to the holiday season ever,\" he said, \"before introducing thousands of more Black Friday &amp; Cyber Monday Weekend deals.\"</p>\n<p>Overall, Anmuth said, he believes the decision to accelerate the timing of holiday deals indicates Amazon \"already maintains significant inventory into the holiday season and is well-equipped to handle elevated holiday demand.\"</p>\n<p>\"Most importantly,\" he said, \"we believe pulling forward holiday promotions should help Amazon efficiently manage through current macro supply chain congestions and minimize gaps in first party and third-party inventory and delivery delays.\"</p>\n<p>Amazon has doubled fulfillment capacity since the pandemic began, the analyst said, and is now caught up on capacity, even pulling forward some 2022 fulfillment/distribution network into 2H21, which could drive an easing level of investment into next year.</p>\n<p>The analyst said he expects U.S. online holiday sales to grow more than 14.5% year-over-year, coming off of outsized pandemic-driven growth of more than 32% year-over-year during the 2020 holiday.</p>\n<p>He said key drivers include strong consumer confidence, increased disposable income, resurgence of brick and mortar retail sales following pandemic constraints and lockdowns in 2020, and one more shopping day between Thanksgiving and Christmas.</p>\n<p>\"While port congestion issues persist, we believe the Port of LA/Long Beach transitioning to 24/7 operation increases throughput and should help truncate wait times,\" he said.</p>\n<p>Separately Guggenheim, analyst Seth Sigman assumed coverage of Amazon on Monday with a buy rating and $4,300 price target.</p>\n<p>Sigman said in research note that he&nbsp;sees potential for a \"significant positive inflection\" in early/mid 2022 for Amazon compared with its moderating sales and margin trends more recently.</p>\n<p>The analyst, who launched coverage on direct-to-consumer e-commerce stocks, said he is positive on the group entering fiscal 2022.</p>\n<p>Online channel share gains should reaccelerate early next year after months of declines and normalizing consumer spending growth may be good for the stocks,&nbsp;Sigman said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon 'Well-Positioned' Going into the Holidays, JPMorgan Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon 'Well-Positioned' Going into the Holidays, JPMorgan Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-25 08:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/amazon-well-positioned-going-into-the-holidays-jpmorgan-says><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amazon should surpass Walmart as the largest U.S. retailer in 2022, a JPMorgan analyst says.\nAmazon is well-positioned going into the holidays, a JPMorgan analyst said Wednesday, and should surpass ...</p>\n\n<a href=\"https://www.thestreet.com/investing/amazon-well-positioned-going-into-the-holidays-jpmorgan-says\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊"},"source_url":"https://www.thestreet.com/investing/amazon-well-positioned-going-into-the-holidays-jpmorgan-says","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176842797","content_text":"Amazon should surpass Walmart as the largest U.S. retailer in 2022, a JPMorgan analyst says.\nAmazon is well-positioned going into the holidays, a JPMorgan analyst said Wednesday, and should surpass Walmart as the largest U.S. retailer in 2022.\nAnalyst Doug Anmuth said in a research report he continues to expect a strong online holiday season, \"albeit against tougher comps and with a resurgence in physical retail.\"\n\"Amazon is well-positioned, having doubled its fulfillment network over the past 2 years, and should remain about 40% of US e-comm spend,\" Anmuth said. \"Amazon remains our top overall idea.\"\nThe analyst said he believes Amazon will surpass Walmart as the largest U.S. retailer in 2022.\n\"Amazon started offering Black Friday deals on 10/4, the earliest start to the holiday season ever,\" he said, \"before introducing thousands of more Black Friday & Cyber Monday Weekend deals.\"\nOverall, Anmuth said, he believes the decision to accelerate the timing of holiday deals indicates Amazon \"already maintains significant inventory into the holiday season and is well-equipped to handle elevated holiday demand.\"\n\"Most importantly,\" he said, \"we believe pulling forward holiday promotions should help Amazon efficiently manage through current macro supply chain congestions and minimize gaps in first party and third-party inventory and delivery delays.\"\nAmazon has doubled fulfillment capacity since the pandemic began, the analyst said, and is now caught up on capacity, even pulling forward some 2022 fulfillment/distribution network into 2H21, which could drive an easing level of investment into next year.\nThe analyst said he expects U.S. online holiday sales to grow more than 14.5% year-over-year, coming off of outsized pandemic-driven growth of more than 32% year-over-year during the 2020 holiday.\nHe said key drivers include strong consumer confidence, increased disposable income, resurgence of brick and mortar retail sales following pandemic constraints and lockdowns in 2020, and one more shopping day between Thanksgiving and Christmas.\n\"While port congestion issues persist, we believe the Port of LA/Long Beach transitioning to 24/7 operation increases throughput and should help truncate wait times,\" he said.\nSeparately Guggenheim, analyst Seth Sigman assumed coverage of Amazon on Monday with a buy rating and $4,300 price target.\nSigman said in research note that he sees potential for a \"significant positive inflection\" in early/mid 2022 for Amazon compared with its moderating sales and margin trends more recently.\nThe analyst, who launched coverage on direct-to-consumer e-commerce stocks, said he is positive on the group entering fiscal 2022.\nOnline channel share gains should reaccelerate early next year after months of declines and normalizing consumer spending growth may be good for the stocks, Sigman said.","news_type":1,"symbols_score_info":{"AMZN":0.9}},"isVote":1,"tweetType":1,"viewCount":871,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875820421,"gmtCreate":1637633429828,"gmtModify":1637633430018,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/875820421","repostId":"1192554686","repostType":4,"repost":{"id":"1192554686","kind":"news","pubTimestamp":1637629334,"share":"https://www.laohu8.com/m/news/1192554686?lang=&edition=full","pubTime":"2021-11-23 09:02","market":"us","language":"en","title":"Samsung to Choose Taylor, Texas, for $17 Billion Chipmaking Factory","url":"https://stock-news.laohu8.com/highlight/detail?id=1192554686","media":"The Wall Street Journal","summary":"The announcement is expected at Tuesday event to be attended by Texas Gov. Greg Abbott, sources say\n","content":"<p>The announcement is expected at Tuesday event to be attended by Texas Gov. Greg Abbott, sources say</p>\n<p>Samsung&nbsp;Electronics Co. plans to&nbsp;build a roughly $17 billion chip-making plant&nbsp;in Taylor, Texas, according to people familiar with the matter, a mega investment by the South Korean tech giant, as the Biden administration pushes for an expansion of U.S. semiconductor production.</p>\n<p>An announcement could come as early as Tuesday, people familiar with the matter said. Gov. Greg Abbott is scheduled to make an “economic announcement” Tuesday at 5 p.m. local time.</p>\n<p>The Taylor facility, located in central Texas, plans to create around 1,800 jobs, though chip production is not expected to start until the end of 2024, according to documents Samsung had previously filed with Texas authorities. To woo Samsung, Taylor had offered incentives that include the equivalent of property-tax breaks of up to 92.5% for the first 10 years, with the write-offs gradually declining over the next several decades.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Samsung to Choose Taylor, Texas, for $17 Billion Chipmaking Factory</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSamsung to Choose Taylor, Texas, for $17 Billion Chipmaking Factory\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-23 09:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/samsung-to-choose-taylor-texas-for-17-billion-chipmaking-factory-11637627613?mod=hp_lista_pos2><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The announcement is expected at Tuesday event to be attended by Texas Gov. Greg Abbott, sources say\nSamsung Electronics Co. plans to build a roughly $17 billion chip-making plant in Taylor, Texas, ...</p>\n\n<a href=\"https://www.wsj.com/articles/samsung-to-choose-taylor-texas-for-17-billion-chipmaking-factory-11637627613?mod=hp_lista_pos2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SSNLF":"三星电子"},"source_url":"https://www.wsj.com/articles/samsung-to-choose-taylor-texas-for-17-billion-chipmaking-factory-11637627613?mod=hp_lista_pos2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192554686","content_text":"The announcement is expected at Tuesday event to be attended by Texas Gov. Greg Abbott, sources say\nSamsung Electronics Co. plans to build a roughly $17 billion chip-making plant in Taylor, Texas, according to people familiar with the matter, a mega investment by the South Korean tech giant, as the Biden administration pushes for an expansion of U.S. semiconductor production.\nAn announcement could come as early as Tuesday, people familiar with the matter said. Gov. Greg Abbott is scheduled to make an “economic announcement” Tuesday at 5 p.m. local time.\nThe Taylor facility, located in central Texas, plans to create around 1,800 jobs, though chip production is not expected to start until the end of 2024, according to documents Samsung had previously filed with Texas authorities. To woo Samsung, Taylor had offered incentives that include the equivalent of property-tax breaks of up to 92.5% for the first 10 years, with the write-offs gradually declining over the next several decades.","news_type":1,"symbols_score_info":{"SSNLF":0.9}},"isVote":1,"tweetType":1,"viewCount":728,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872565417,"gmtCreate":1637549083380,"gmtModify":1637549127663,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/872565417","repostId":"2185826127","repostType":4,"isVote":1,"tweetType":1,"viewCount":601,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872800284,"gmtCreate":1637465891041,"gmtModify":1637465891154,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/872800284","repostId":"1193739210","repostType":4,"repost":{"id":"1193739210","kind":"news","pubTimestamp":1637457862,"share":"https://www.laohu8.com/m/news/1193739210?lang=&edition=full","pubTime":"2021-11-21 09:24","market":"us","language":"en","title":"Does Sono Group Have a Breakthrough Innovation That Could Put “Range Anxiety” to Bed?","url":"https://stock-news.laohu8.com/highlight/detail?id=1193739210","media":"Investorplace","summary":"In a blink-and-you-miss-it moment this week, one of the most interestingelectric vehicle (EV) startu","content":"<div>\n<p>In a blink-and-you-miss-it moment this week, one of the most interestingelectric vehicle (EV) startupsin the worldwent publicthrough a super successful initial public offering (IPO).\nThat company is ...</p>\n\n<a href=\"https://investorplace.com/hypergrowthinvesting/2021/11/does-sono-group-have-a-breakthrough-innovation-that-could-put-range-anxiety-to-bed/\">Web Link</a>\n\n</div>\n","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Does Sono Group Have a Breakthrough Innovation That Could Put “Range Anxiety” to Bed?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDoes Sono Group Have a Breakthrough Innovation That Could Put “Range Anxiety” to Bed?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-21 09:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/hypergrowthinvesting/2021/11/does-sono-group-have-a-breakthrough-innovation-that-could-put-range-anxiety-to-bed/><strong>Investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In a blink-and-you-miss-it moment this week, one of the most interestingelectric vehicle (EV) startupsin the worldwent publicthrough a super successful initial public offering (IPO).\nThat company is ...</p>\n\n<a href=\"https://investorplace.com/hypergrowthinvesting/2021/11/does-sono-group-have-a-breakthrough-innovation-that-could-put-range-anxiety-to-bed/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SEV":"Sono Group N.V."},"source_url":"https://investorplace.com/hypergrowthinvesting/2021/11/does-sono-group-have-a-breakthrough-innovation-that-could-put-range-anxiety-to-bed/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1193739210","content_text":"In a blink-and-you-miss-it moment this week, one of the most interestingelectric vehicle (EV) startupsin the worldwent publicthrough a super successful initial public offering (IPO).\nThat company is the Germany-based Sono Group(NASDAQ:SEV) – a small EV company that’s unlike any other electric vehicle firm on the planet. This isn’t the next Tesla(NASDAQ:TSLA),nor is it the next Lucid Group(NASDAQ:LCID) or Rivian(NASDAQ:RIVN)… and that’s by design.\nBecause, while all those EV makers are making plug-in electric vehicles, Sono is making the world’s firstsolar electric vehicle, or “SEV.”\nSoaring 150%-plus from its $15 IPO price Wednesday, investors have sat up to take notice of this company that is helmed by a CEO barely out of university.\nIndeed, at age 26, Sono founder Laurin Hahn cuts a very different image than your typical CEO. Hahn’s an environmentalist and idealist at heart, which is why Sono’s goal isn’t just to sell cars, but to “implement an innovative CO2-neutral mobility concept.” Out of that vision comes the Sion– an understated, no-frills attempt at designing an effective solar EV for the masses.\nAnd unlike the glossy, leather-clad premium electric vehicles dominating most conversations around EVs, the Sion actually feels like a vehicle designed to put the world on the right path toward net-zero carbon emissions.\nTo ensure its vision aligned with the needs of everyday drivers, the company’s signature vehicle – the Sion – had its users in mind from the very beginning. Everything from the color and upholstery of the car to the voltage and resulting range of the battery was voted on by a community of 15,000.\nAs for its look, the Sion essentially replaces the exterior aluminum and paint on an electric car with 248 flexible solar modules that are perfectly adapted to the shape of the vehicle.\nThe car looks, drives, and acts just like any other mass-market EV. But as it drives, it charges itself through these solar cells. There’s a still a battery at the core of the vehicle, but it doesn’t rely on being plugged in – the battery can be recharged by simply leaving it out in the sun.\nThe huge value-add here, of course, is solving so-called EV “range anxiety,” or the fear that EVs won’t be able to drive you as far as you need to go.\nTo-date, such fears have proven very legitimate. After all, your typical EV today fetches around 250 miles of driving range. Your average gas car can travel up to 400 miles per tank. So, yes, EVs have historically been limiting in terms of how far they can travel.\nSono Motors believes that its solar EV tech will fix this issue. And while it is a very innovative solution that we find super interesting, there’s just one small issue:It doesn’t actually solve the “range anxiety” problem.\nSono’s claim is that its solar cells collectively add about 70 miles of driving range to its Sion EV, which has a built-in driving range of 190 miles. Add it up, and even with these solar panels, the Sion still gets less than 300 miles of real-time driving range – much less than the 400 miles a gas-powered car fetches per tank.\nBut solar technology is not static –it’s very dynamic. And right now, scientists across the globe are working on multiple solar technology breakthroughs to dramatically improve the performance of solar cells. One such promising breakthrough is the inclusion of perovskites in solar cells. Perovskites are a very flexible material, and therefore, could be included in Sono’s solar mobility tech to significantly improve the performance of these SEVs.\nIn other words, while solar electric vehicles are cool, the underlying solar cell technology here is still many years away from being robust enough to actually solve EV range anxiety fears.\nThat’s the bad news.\nThe good news, though, is that we don’t evenneedsolar electric vehicles to solve range anxiety…\nBecause there is another breakthrough battery technology being pioneered today, which is ready to add not just 70 or 80 miles of driving range to an EV – but potentially thousands of miles of driving range to an EV, thereby allowing electric cars to travel as much as 10X as far as gas-powered cars on a single charge.\nThese batteries are the future and will forever solve the EV “range anxiety” problem.\nIt’s simple, really… With them, EVs will last forever.\nThe technology behind these forever batteries is exceptionally complex – so complex, in fact, that no one has been able to make one big enough to power an electric car yet.\nBut that’s changing right now, as some companies in this space have – for the first time ever – built small-scale “forever batteries” that are working. Now, all these companies have to do is scale these batteries and make them bigger.\nMake no mistake. They’re going to do just that. And the companies behind this forever battery technology will turn into titans of the EV industry.\nNot to mention,their stocks will score shareholders enormous returns.","news_type":1,"symbols_score_info":{"SEV":0.9}},"isVote":1,"tweetType":1,"viewCount":884,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876699481,"gmtCreate":1637299071469,"gmtModify":1637299071582,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/876699481","repostId":"1148769228","repostType":4,"repost":{"id":"1148769228","kind":"news","pubTimestamp":1637290317,"share":"https://www.laohu8.com/m/news/1148769228?lang=&edition=full","pubTime":"2021-11-19 10:51","market":"us","language":"en","title":"CVS to close 900 drugstores in three years to beef up health services","url":"https://stock-news.laohu8.com/highlight/detail?id=1148769228","media":"Reuters","summary":"(Reuters) - CVS Health Corp(CVS.N)will shut about 900 stores over the next three years, it said on T","content":"<p>(Reuters) - CVS Health Corp(CVS.N)will shut about 900 stores over the next three years, it said on Thursday as the company tries to adapt to changing consumer preferences by pivoting to new store formats that offer more health services.</p>\n<p>Best known for its chain of drugstores in more than 9,900 locations, the company has been working to expand its services since it acquired health insurer Aetna in 2018.</p>\n<p>CVS said that as part of its strategic review it would create an enhanced version of its health hubs that offer treatment for common ailments as well as chronic care to add more customers.</p>\n<p>The reduction in stores will result in CVS taking an impairment charge of between $1 billion and $1.2 billion in the fourth quarter.</p>\n<p>People walk by a CVS pharmacy store in Manhattan, New York City, New York, U.S., November 17, 2021. REUTERS/Andrew Kelly</p>\n<p>As part of the new strategy, the company also created a new position of chief pharmacy officer and appointed executive vice president of specialty pharmacy and product innovation Prem Shah to the role.</p>\n<p>\"We see this as consistent with our expected LT (long-term) strategy for CVS, moving to grow managed care and care delivery, while shrinking legacy bricks-and-mortar retail business,\" said Bernstein analyst Lance Wilkes in a note.</p>\n<p>Rival Walgreens Boots Alliance(WBA.O)also recently shifted focus beyond its drugstores, investing $5.2 billion in VillageMD and $330 million in post-acute and home care provider CareCentrix.read more</p>\n<p>CVS cut its annual 2021 profit per share forecast to between $5.46 and $5.67 from $6.13 to $6.23, but stuck to its adjusted profit view saying there will be no impact from the store closures this year and the next.</p>\n<p>It also said Neela Montgomery, president of CVS Pharmacy, would leave company at the end of 2021.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CVS to close 900 drugstores in three years to beef up health services</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCVS to close 900 drugstores in three years to beef up health services\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-19 10:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/cvs-health-close-stores-record-impairment-charge-2021-11-18/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - CVS Health Corp(CVS.N)will shut about 900 stores over the next three years, it said on Thursday as the company tries to adapt to changing consumer preferences by pivoting to new store ...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/cvs-health-close-stores-record-impairment-charge-2021-11-18/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CVS":"西维斯健康"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/cvs-health-close-stores-record-impairment-charge-2021-11-18/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148769228","content_text":"(Reuters) - CVS Health Corp(CVS.N)will shut about 900 stores over the next three years, it said on Thursday as the company tries to adapt to changing consumer preferences by pivoting to new store formats that offer more health services.\nBest known for its chain of drugstores in more than 9,900 locations, the company has been working to expand its services since it acquired health insurer Aetna in 2018.\nCVS said that as part of its strategic review it would create an enhanced version of its health hubs that offer treatment for common ailments as well as chronic care to add more customers.\nThe reduction in stores will result in CVS taking an impairment charge of between $1 billion and $1.2 billion in the fourth quarter.\nPeople walk by a CVS pharmacy store in Manhattan, New York City, New York, U.S., November 17, 2021. REUTERS/Andrew Kelly\nAs part of the new strategy, the company also created a new position of chief pharmacy officer and appointed executive vice president of specialty pharmacy and product innovation Prem Shah to the role.\n\"We see this as consistent with our expected LT (long-term) strategy for CVS, moving to grow managed care and care delivery, while shrinking legacy bricks-and-mortar retail business,\" said Bernstein analyst Lance Wilkes in a note.\nRival Walgreens Boots Alliance(WBA.O)also recently shifted focus beyond its drugstores, investing $5.2 billion in VillageMD and $330 million in post-acute and home care provider CareCentrix.read more\nCVS cut its annual 2021 profit per share forecast to between $5.46 and $5.67 from $6.13 to $6.23, but stuck to its adjusted profit view saying there will be no impact from the store closures this year and the next.\nIt also said Neela Montgomery, president of CVS Pharmacy, would leave company at the end of 2021.","news_type":1,"symbols_score_info":{"CVS":0.9}},"isVote":1,"tweetType":1,"viewCount":580,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871712954,"gmtCreate":1637112106105,"gmtModify":1637112106415,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/871712954","repostId":"2184873748","repostType":4,"repost":{"id":"2184873748","kind":"news","pubTimestamp":1637110327,"share":"https://www.laohu8.com/m/news/2184873748?lang=&edition=full","pubTime":"2021-11-17 08:52","market":"sg","language":"en","title":"Singapore non-oil exports strengthen with 17.9% jump in October","url":"https://stock-news.laohu8.com/highlight/detail?id=2184873748","media":"The Straits Times","summary":"SINGAPORE - Singapore's non-oil domestic exports (Nodx) expanded in October at a faster pace than la","content":"<div>\n<p>SINGAPORE - Singapore's non-oil domestic exports (Nodx) expanded in October at a faster pace than last month, driven by growth in both electronics and non-electronics shipments.\nNodx rose by 17.9 per ...</p>\n\n<a href=\"http://www.straitstimes.com/business/economy/singapore-non-oil-exports-strengthen-with-179-jump-in-october\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore non-oil exports strengthen with 17.9% jump in October</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore non-oil exports strengthen with 17.9% jump in October\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-17 08:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/business/economy/singapore-non-oil-exports-strengthen-with-179-jump-in-october><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SINGAPORE - Singapore's non-oil domestic exports (Nodx) expanded in October at a faster pace than last month, driven by growth in both electronics and non-electronics shipments.\nNodx rose by 17.9 per ...</p>\n\n<a href=\"http://www.straitstimes.com/business/economy/singapore-non-oil-exports-strengthen-with-179-jump-in-october\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"http://www.straitstimes.com/business/economy/singapore-non-oil-exports-strengthen-with-179-jump-in-october","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2184873748","content_text":"SINGAPORE - Singapore's non-oil domestic exports (Nodx) expanded in October at a faster pace than last month, driven by growth in both electronics and non-electronics shipments.\nNodx rose by 17.9 per cent in October, rising for an 11th consecutive month, following a revised 12 per cent increase in September, said Enterprise Singapore (ESG) on Wednesday (Nov 17).\nThe pace of annual growth was quicker than the 15.1 per cent forecast by economists in a Bloomberg poll.\nOn a month-on-month seasonally adjusted basis, Nodx increased by 4.2 per cent last month, after September's 1 per cent rise, ESG data showed.\nESG said Nodx growth over the year was led by non-electronic goods such as non-monetary gold, specialised machinery and petrochemicals.\nNon-electronic shipments grew by 18.9 per cent in October, following the 11.4 percent rise in the previous month.\nNon-monetary gold shipments surged 223.2 per cent, specialised machinery grew 49.3 per cent and petrochemicals rose 39.1 per cent.\nThe linchpin electronics sector saw exports expand by 14.9 per cent year-on-year, extending the 14.1 per cent gain in September.\nIntegrated circuits' shipments rose 22.6 per cent, PCs were up 18.1 per cent, and export of diodes and transistors rose by 19.8 per cent.\nNodx to the top markets as a whole rose in October, though exports to Thailand, the US and Hong Kong declined. The largest contributors to the rise in October Nodx were China, Malaysia.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":668,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871334657,"gmtCreate":1637025375997,"gmtModify":1637025376102,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"&nbsp;Good","listText":"&nbsp;Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/871334657","repostId":"1140879609","repostType":4,"isVote":1,"tweetType":1,"viewCount":1190,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873591395,"gmtCreate":1636956756661,"gmtModify":1636956756779,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/873591395","repostId":"1136859135","repostType":4,"repost":{"id":"1136859135","kind":"news","pubTimestamp":1636947003,"share":"https://www.laohu8.com/m/news/1136859135?lang=&edition=full","pubTime":"2021-11-15 11:30","market":"us","language":"en","title":"Pfizer’s Big Gamble Is Paying Off. Its Stock Is a Good Long-Term Bet.","url":"https://stock-news.laohu8.com/highlight/detail?id=1136859135","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p>\n<p>“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p>\n<p>Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p>\n<p>Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p>\n<p>In a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.</p>\n<p>The new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p>\n<p>Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson &amp; Johnson (JNJ) and Eli Lilly (LLY).</p>\n<p>The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p>\n<p>The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.<img src=\"https://static.tigerbbs.com/7b64a90a2587bba33128c2a9cf35a596\" tg-width=\"961\" tg-height=\"647\" width=\"100%\" height=\"auto\">The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p>\n<p>While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p>\n<p>In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p>\n<p>The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p>\n<p>“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p>\n<p>Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p>\n<p>The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p>\n<p>“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p>\n<p>Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).</p>\n<p>“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p>\n<p>Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p>\n<p>“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p>\n<p>That makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p>\n<p>Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p>\n<p>Moderna shares are down more than 40% over the past three months.</p>\n<p>As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p>\n<p>When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p>\n<p>That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p>\n<p>Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p>\n<p>Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p>\n<p>An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer’s Big Gamble Is Paying Off. Its Stock Is a Good Long-Term Bet.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer’s Big Gamble Is Paying Off. Its Stock Is a Good Long-Term Bet.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-15 11:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=newsviewer_click><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that...</p>\n\n<a href=\"https://www.marketwatch.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=newsviewer_click\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.marketwatch.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=newsviewer_click","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1136859135","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":879,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":865832907,"gmtCreate":1632966196232,"gmtModify":1632966196420,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/865832907","repostId":"1104172212","repostType":4,"isVote":1,"tweetType":1,"viewCount":492,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":815864853,"gmtCreate":1630667298872,"gmtModify":1631892030480,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/815864853","repostId":"2164876904","repostType":4,"isVote":1,"tweetType":1,"viewCount":438,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":841156816,"gmtCreate":1635897806335,"gmtModify":1635897806453,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/841156816","repostId":"2180736486","repostType":4,"isVote":1,"tweetType":1,"viewCount":705,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":814461179,"gmtCreate":1630871614591,"gmtModify":1631892030473,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/814461179","repostId":"2164808914","repostType":4,"isVote":1,"tweetType":1,"viewCount":308,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":816953230,"gmtCreate":1630462036820,"gmtModify":1631892030493,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/816953230","repostId":"1193943153","repostType":4,"isVote":1,"tweetType":1,"viewCount":579,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":831323954,"gmtCreate":1629290213878,"gmtModify":1631893805374,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Ok&nbsp;","listText":"Ok&nbsp;","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/831323954","repostId":"1131876419","repostType":4,"repost":{"id":"1131876419","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1629288195,"share":"https://www.laohu8.com/m/news/1131876419?lang=&edition=full","pubTime":"2021-08-18 20:03","market":"us","language":"en","title":"Toplines Before US Market Opens Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1131876419","media":"Tiger Newspress","summary":"US equity futures and global markets were flat in listless trading as investors assessed the outlook","content":"<p>US equity futures and global markets were flat in listless trading as investors assessed the outlook for economic recovery and awaited the latest Federal Reserve minutes to gauge the direction of monetary policy while tracking the latest covid lockdown in New Zealand and on edge ahead of possible turbulence in Friday's OpEx. </p>\n<p>Overnight the MSCI Asia Pacific Index added 0.4% while Japan’s Topix index closed 0.4% higher. In Europe the Stoxx 600 Index was broadly unchanged. S&amp;P 500 futures pointed to a small move lower at the open, the 10-year Treasury yield was at 1.277%, oil rose and gold moved higher, while cryptos rebounded from a late Tuesday selloff.</p>\n<p>At 7:55 a.m. ET, Dow E-minis were down 64 points, or 0.18%, S&amp;P 500 E-minis were down&nbsp;4 points, or 0.09% and Nasdaq 100 E-minis were&nbsp;up&nbsp;8 points, or 0.05%.</p>\n<p><img src=\"https://static.tigerbbs.com/5b8765de5383459e16baef1249617b5b\" tg-width=\"1125\" tg-height=\"413\" width=\"100%\" height=\"auto\"></p>\n<h3><b>Stocks making the biggest moves in the premarket:</b></h3>\n<p>1.&nbsp;<b><a href=\"https://laohu8.com/S/LOW\">Lowe's</a></b> – The home improvement retailer reported an adjusted quarterly profit of $4.25 per share, beating the consensus estimate of $4.01. Revenue beat forecasts, and the same-store sales decline of 1.6% was less than the 2.2% decline predicted by analysts. Lowe’s also raised its full-year financial outlook, as spending by builders and professionals rose. Lowe’s rallied 4.60% in the premarket.</p>\n<p>2.&nbsp;<b><a href=\"https://laohu8.com/S/TGT\">Target</a> </b>– The retailer beat estimates by 15 cents with adjusted quarterly earnings of $3.64 per share, and revenue slightly above analyst forecasts. Comparable store sales rose 8.9%, slightly above the 8.8% consensus estimate. Target shares added 2.42% in premarket trading.</p>\n<p>3.&nbsp;<b><a href=\"https://laohu8.com/S/DNUT\">Krispy Kreme, Inc.</a></b> – The doughnut chain fell a penny shy of Street forecasts with an adjusted quarterly profit of 13 cents per share, though revenue did beat estimates. Krispy Kreme also gave a better-than-expected revenue forecast, based on projected strength from online ordering and new menu items. The stock added 2.9% in premarket action.</p>\n<p>4.&nbsp;<b><a href=\"https://laohu8.com/S/ALC\">Alcon Inc.</a></b> – The maker of eyecare and surgical products surged 9.89% in the premarket, after reporting better-than-expected quarterly results and raising its full-year guidance. The quarter marked the debut of Alcon’s Vivity intraocular contact lens, which analysts say will help drive sales growth.</p>\n<p>5.&nbsp;<b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> </b>– Moderna rose 1.74% in premarket trading while BioNTech gained 1.38%, ahead of an expected announcement by the White House calling for a booster shot for Americans already fully vaccinated against Covid-19.</p>\n<p>6.&nbsp;<b><a href=\"https://laohu8.com/S/TMUS\">T-Mobile US</a></b> – Following an investigation, the wireless carrier now says the personal information of about 7.8 million customers was compromised in a recent data breach. That included dates of birth, social security numbers and driver’s license information, although no financial information was stolen.</p>\n<p>7.&nbsp;<b><a href=\"https://laohu8.com/S/VIAC\">Viacom CBS</a> </b>– Shares of the media giant gained 2.77% in premarket action after Wells Fargo Securities upgraded the stock to “overweight” from “equal weight”. Wells Fargo said ViacomCBS is one of the players poised to benefit from industry consolidation and it is also impressed by the upcoming programming slate for the company’s Paramount+ streaming service.</p>\n<p>8. <b><a href=\"https://laohu8.com/S/BB\">BlackBerry</a></b> – The communications software maker said it released software patches to fix an issue with older versions of its QNX operating system and has notified all customers. U.S. officials had said earlier yesterday that the software flaw could put cars and medical equipment at risk. BlackBerry shares gained 1.34% in the premarket.</p>\n<p>9.&nbsp;<b><a href=\"https://laohu8.com/S/TLRY\">Tilray Inc.</a></b> – The Canada-based cannabis producer’s shares surged 9.22% in premarket trading, after striking a deal to buy $166 million in convertible debt of U.S. producer MedMen Enterprises. Canadian producers cannot yet directly own a U.S.-based marijuana business, but Tilray could be poised to benefit from the deal if and when U.S. laws change.</p>\n<p>10.&nbsp;<b><a href=\"https://laohu8.com/S/A\">Agilent</a> Technologies</b>&nbsp;– Agilent gained 2.39% in the premarket after the life sciences company beat top and bottom-line estimates for its latest quarter and raised its full-year forecast. Agilent said its metrics were upbeat across all its units and added that its non-Covid diagnostics business has recovered beyond pre-pandemic levels.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Opens Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Opens Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-18 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>US equity futures and global markets were flat in listless trading as investors assessed the outlook for economic recovery and awaited the latest Federal Reserve minutes to gauge the direction of monetary policy while tracking the latest covid lockdown in New Zealand and on edge ahead of possible turbulence in Friday's OpEx. </p>\n<p>Overnight the MSCI Asia Pacific Index added 0.4% while Japan’s Topix index closed 0.4% higher. In Europe the Stoxx 600 Index was broadly unchanged. S&amp;P 500 futures pointed to a small move lower at the open, the 10-year Treasury yield was at 1.277%, oil rose and gold moved higher, while cryptos rebounded from a late Tuesday selloff.</p>\n<p>At 7:55 a.m. ET, Dow E-minis were down 64 points, or 0.18%, S&amp;P 500 E-minis were down&nbsp;4 points, or 0.09% and Nasdaq 100 E-minis were&nbsp;up&nbsp;8 points, or 0.05%.</p>\n<p><img src=\"https://static.tigerbbs.com/5b8765de5383459e16baef1249617b5b\" tg-width=\"1125\" tg-height=\"413\" width=\"100%\" height=\"auto\"></p>\n<h3><b>Stocks making the biggest moves in the premarket:</b></h3>\n<p>1.&nbsp;<b><a href=\"https://laohu8.com/S/LOW\">Lowe's</a></b> – The home improvement retailer reported an adjusted quarterly profit of $4.25 per share, beating the consensus estimate of $4.01. Revenue beat forecasts, and the same-store sales decline of 1.6% was less than the 2.2% decline predicted by analysts. Lowe’s also raised its full-year financial outlook, as spending by builders and professionals rose. Lowe’s rallied 4.60% in the premarket.</p>\n<p>2.&nbsp;<b><a href=\"https://laohu8.com/S/TGT\">Target</a> </b>– The retailer beat estimates by 15 cents with adjusted quarterly earnings of $3.64 per share, and revenue slightly above analyst forecasts. Comparable store sales rose 8.9%, slightly above the 8.8% consensus estimate. Target shares added 2.42% in premarket trading.</p>\n<p>3.&nbsp;<b><a href=\"https://laohu8.com/S/DNUT\">Krispy Kreme, Inc.</a></b> – The doughnut chain fell a penny shy of Street forecasts with an adjusted quarterly profit of 13 cents per share, though revenue did beat estimates. Krispy Kreme also gave a better-than-expected revenue forecast, based on projected strength from online ordering and new menu items. The stock added 2.9% in premarket action.</p>\n<p>4.&nbsp;<b><a href=\"https://laohu8.com/S/ALC\">Alcon Inc.</a></b> – The maker of eyecare and surgical products surged 9.89% in the premarket, after reporting better-than-expected quarterly results and raising its full-year guidance. The quarter marked the debut of Alcon’s Vivity intraocular contact lens, which analysts say will help drive sales growth.</p>\n<p>5.&nbsp;<b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> </b>– Moderna rose 1.74% in premarket trading while BioNTech gained 1.38%, ahead of an expected announcement by the White House calling for a booster shot for Americans already fully vaccinated against Covid-19.</p>\n<p>6.&nbsp;<b><a href=\"https://laohu8.com/S/TMUS\">T-Mobile US</a></b> – Following an investigation, the wireless carrier now says the personal information of about 7.8 million customers was compromised in a recent data breach. That included dates of birth, social security numbers and driver’s license information, although no financial information was stolen.</p>\n<p>7.&nbsp;<b><a href=\"https://laohu8.com/S/VIAC\">Viacom CBS</a> </b>– Shares of the media giant gained 2.77% in premarket action after Wells Fargo Securities upgraded the stock to “overweight” from “equal weight”. Wells Fargo said ViacomCBS is one of the players poised to benefit from industry consolidation and it is also impressed by the upcoming programming slate for the company’s Paramount+ streaming service.</p>\n<p>8. <b><a href=\"https://laohu8.com/S/BB\">BlackBerry</a></b> – The communications software maker said it released software patches to fix an issue with older versions of its QNX operating system and has notified all customers. U.S. officials had said earlier yesterday that the software flaw could put cars and medical equipment at risk. BlackBerry shares gained 1.34% in the premarket.</p>\n<p>9.&nbsp;<b><a href=\"https://laohu8.com/S/TLRY\">Tilray Inc.</a></b> – The Canada-based cannabis producer’s shares surged 9.22% in premarket trading, after striking a deal to buy $166 million in convertible debt of U.S. producer MedMen Enterprises. Canadian producers cannot yet directly own a U.S.-based marijuana business, but Tilray could be poised to benefit from the deal if and when U.S. laws change.</p>\n<p>10.&nbsp;<b><a href=\"https://laohu8.com/S/A\">Agilent</a> Technologies</b>&nbsp;– Agilent gained 2.39% in the premarket after the life sciences company beat top and bottom-line estimates for its latest quarter and raised its full-year forecast. Agilent said its metrics were upbeat across all its units and added that its non-Covid diagnostics business has recovered beyond pre-pandemic levels.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BB":"黑莓","MRNA":"Moderna, Inc.","A":"安捷伦科技","TGT":"塔吉特","BNTX":"BioNTech SE","LOW":"劳氏","TLRY":"Tilray Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131876419","content_text":"US equity futures and global markets were flat in listless trading as investors assessed the outlook for economic recovery and awaited the latest Federal Reserve minutes to gauge the direction of monetary policy while tracking the latest covid lockdown in New Zealand and on edge ahead of possible turbulence in Friday's OpEx. \nOvernight the MSCI Asia Pacific Index added 0.4% while Japan’s Topix index closed 0.4% higher. In Europe the Stoxx 600 Index was broadly unchanged. S&P 500 futures pointed to a small move lower at the open, the 10-year Treasury yield was at 1.277%, oil rose and gold moved higher, while cryptos rebounded from a late Tuesday selloff.\nAt 7:55 a.m. ET, Dow E-minis were down 64 points, or 0.18%, S&P 500 E-minis were down 4 points, or 0.09% and Nasdaq 100 E-minis were up 8 points, or 0.05%.\n\nStocks making the biggest moves in the premarket:\n1. Lowe's – The home improvement retailer reported an adjusted quarterly profit of $4.25 per share, beating the consensus estimate of $4.01. Revenue beat forecasts, and the same-store sales decline of 1.6% was less than the 2.2% decline predicted by analysts. Lowe’s also raised its full-year financial outlook, as spending by builders and professionals rose. Lowe’s rallied 4.60% in the premarket.\n2. Target – The retailer beat estimates by 15 cents with adjusted quarterly earnings of $3.64 per share, and revenue slightly above analyst forecasts. Comparable store sales rose 8.9%, slightly above the 8.8% consensus estimate. Target shares added 2.42% in premarket trading.\n3. Krispy Kreme, Inc. – The doughnut chain fell a penny shy of Street forecasts with an adjusted quarterly profit of 13 cents per share, though revenue did beat estimates. Krispy Kreme also gave a better-than-expected revenue forecast, based on projected strength from online ordering and new menu items. The stock added 2.9% in premarket action.\n4. Alcon Inc. – The maker of eyecare and surgical products surged 9.89% in the premarket, after reporting better-than-expected quarterly results and raising its full-year guidance. The quarter marked the debut of Alcon’s Vivity intraocular contact lens, which analysts say will help drive sales growth.\n5. Moderna, Inc., BioNTech SE – Moderna rose 1.74% in premarket trading while BioNTech gained 1.38%, ahead of an expected announcement by the White House calling for a booster shot for Americans already fully vaccinated against Covid-19.\n6. T-Mobile US – Following an investigation, the wireless carrier now says the personal information of about 7.8 million customers was compromised in a recent data breach. That included dates of birth, social security numbers and driver’s license information, although no financial information was stolen.\n7. Viacom CBS – Shares of the media giant gained 2.77% in premarket action after Wells Fargo Securities upgraded the stock to “overweight” from “equal weight”. Wells Fargo said ViacomCBS is one of the players poised to benefit from industry consolidation and it is also impressed by the upcoming programming slate for the company’s Paramount+ streaming service.\n8. BlackBerry – The communications software maker said it released software patches to fix an issue with older versions of its QNX operating system and has notified all customers. U.S. officials had said earlier yesterday that the software flaw could put cars and medical equipment at risk. BlackBerry shares gained 1.34% in the premarket.\n9. Tilray Inc. – The Canada-based cannabis producer’s shares surged 9.22% in premarket trading, after striking a deal to buy $166 million in convertible debt of U.S. producer MedMen Enterprises. Canadian producers cannot yet directly own a U.S.-based marijuana business, but Tilray could be poised to benefit from the deal if and when U.S. laws change.\n10. Agilent Technologies – Agilent gained 2.39% in the premarket after the life sciences company beat top and bottom-line estimates for its latest quarter and raised its full-year forecast. Agilent said its metrics were upbeat across all its units and added that its non-Covid diagnostics business has recovered beyond pre-pandemic levels.","news_type":1,"symbols_score_info":{"A":0.9,"BB":0.9,"BNTX":0.9,"LOW":0.9,"MRNA":0.9,"TGT":0.9,"TLRY":0.9,"VIAC":0.9}},"isVote":1,"tweetType":1,"viewCount":344,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":845047467,"gmtCreate":1636257556096,"gmtModify":1636257565036,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"&nbsp;Fokf","listText":"&nbsp;Fokf","text":"Fokf","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/845047467","repostId":"2181974224","repostType":4,"isVote":1,"tweetType":1,"viewCount":498,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849181408,"gmtCreate":1635734912777,"gmtModify":1635734912902,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/849181408","repostId":"1150912013","repostType":4,"repost":{"id":"1150912013","kind":"news","pubTimestamp":1635724788,"share":"https://www.laohu8.com/m/news/1150912013?lang=&edition=full","pubTime":"2021-11-01 07:59","market":"us","language":"en","title":"What's the best month for stocks? Hint: the next four weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=1150912013","media":"finance.yahoo","summary":"The stock market’s record run is poised to gain steam in the weeks ahead — if history is any indication.The start of the holiday season is typically a strong time of year on Wall Street, a pattern that analysts point to as a reason to remain optimistic that the stock market will remain at all-time highs following a turbulent September.Historically, November has been the best month of the year for the stock market—both since 1950 and over the past decade, according to LPL Financial.“November is t","content":"<p>The stock market’s record run is poised to gain steam in the weeks ahead — if history is any indication.</p>\n<p>The start of the holiday season is typically a strong time of year on Wall Street, a pattern that analysts point to as a reason to remain optimistic that the stock market will remain at all-time highs following a turbulent September.</p>\n<p>Historically, November has been the best month of the year for the stock market—both since 1950 and over the past decade, according to LPL Financial.</p>\n<p>That’s not all. History shows the stock market’s strongest six-month period is November to April, according to the Stock Trader’s Almanac. November is also the first month of the market’s best three-month stretch, November to January.</p>\n<p>Why is November the best?</p>\n<p>This seasonal strength is created by a combination of factors. For one thing, the final three months of the year are typically the best for stocks, with stocks rising 3.8% on average, according to LPL Financial.</p>\n<p>Strong spending by shoppers during the holidays also tends to translate into strong quarters for consumer-focused businesses. Some analysts also attribute it to optimism during the holiday season, year-end portfolio adjustments and investors being on vacation.</p>\n<p>“November is the best month of the year, but it doesn’t seem to get nearly as much love as you’d think,” Ryan Detrick, chief market strategist at LPL Financial, said in a note to clients. “We all assume December is the best month, but November is actually better and gets very little fanfare. Maybe it should be a month for the bulls, not for turkeys.”</p>\n<p>Wall Street avoids spooky October</p>\n<p>While October is often considered a spooky month for investors, earning a bad reputation following the crashes of 1929, 1987 and during the global financial crisis in 2008, investors weren’t so fearful this year.</p>\n<p>After the S&amp;P 500 recorded its biggest monthly loss since the start of the coronavirus pandemic in September, the broad index rebounded more than 6% in October on further signs that corporate profits are growing once again following last year's recession.</p>\n<p>“It looks as though the market has resisted ‘Octoberphobia’ and averted the feared crashes or massacres that have given the month its bad reputation,” Jeff Hirsch, editor of the Stock Trader's Almanac, said in a note to clients.</p>\n<p>To be sure, November has taken hits during bear markets, when major averages drop more than 20% from a recent peak.</p>\n<p>For instance, November 2000 was the Nasdaq Composite’s second-worst month on record, with the technology-focused index plunging nearly 23%, according to the Stock Trader’s Almanac. Only October 1987 was worse, and that is when the \"Black Monday\" stock market crash occurred</p>\n<p>Why investors should be optimistic</p>\n<p>The U.S. economy&nbsp;slowed substantially from July through September&nbsp;following a series of obstacles, including a surge in COVID-19 cases, supply chain bottlenecks, rising consumer prices and the fading effects of federal stimulus measures.</p>\n<p>But with COVID-19 cases now falling and vaccinations rising, most economists are branding the weak showing a soft patch in a still-robust recovery from the pandemic-induced recession, with a healthy rebound projected in the final months of the year.</p>\n<p>There are signs that there could be more gains to come on Wall Street in the final months of the year on strong seasonality trends, better-than-expected corporate earnings and falling COVID-19 cases. Market breadth has also improved, meaning that more stocks are participating in the rally, a sign of a healthy and strong market.</p>\n<p>Jobless claims have also fallen steadily in recent weeks, with continuing claims sliding below 2.5 million recently for the first time since the coronavirus pandemic began.</p>\n<p>After suffering its first 5% pullback of 2021 in early October, the S&amp;P 500 has come roaring back and closed at a record high on October 21. The S&amp;P 500 Index has gained more than 20% so far this year, making more than 50 record highs along the way.</p>\n<p>That could be a positive sign for investors in the coming months. The past seven times the S&amp;P 500 had risen 15% for the year heading into the fourth quarter, that final quarter ended up higher each time, rising 5.8%, data from LPL Financial showed.</p>\n<p>“We firmly believe that new highs are something to be embraced, not feared, and history shows that new highs tend to come in bunches—something that has certainly been true so far this year,” according to Detrick.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What's the best month for stocks? Hint: the next four weeks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat's the best month for stocks? Hint: the next four weeks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-01 07:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/whats-best-month-stocks-hint-110106336.html><strong>finance.yahoo</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market’s record run is poised to gain steam in the weeks ahead — if history is any indication.\nThe start of the holiday season is typically a strong time of year on Wall Street, a pattern ...</p>\n\n<a href=\"https://finance.yahoo.com/news/whats-best-month-stocks-hint-110106336.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"source_url":"https://finance.yahoo.com/news/whats-best-month-stocks-hint-110106336.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150912013","content_text":"The stock market’s record run is poised to gain steam in the weeks ahead — if history is any indication.\nThe start of the holiday season is typically a strong time of year on Wall Street, a pattern that analysts point to as a reason to remain optimistic that the stock market will remain at all-time highs following a turbulent September.\nHistorically, November has been the best month of the year for the stock market—both since 1950 and over the past decade, according to LPL Financial.\nThat’s not all. History shows the stock market’s strongest six-month period is November to April, according to the Stock Trader’s Almanac. November is also the first month of the market’s best three-month stretch, November to January.\nWhy is November the best?\nThis seasonal strength is created by a combination of factors. For one thing, the final three months of the year are typically the best for stocks, with stocks rising 3.8% on average, according to LPL Financial.\nStrong spending by shoppers during the holidays also tends to translate into strong quarters for consumer-focused businesses. Some analysts also attribute it to optimism during the holiday season, year-end portfolio adjustments and investors being on vacation.\n“November is the best month of the year, but it doesn’t seem to get nearly as much love as you’d think,” Ryan Detrick, chief market strategist at LPL Financial, said in a note to clients. “We all assume December is the best month, but November is actually better and gets very little fanfare. Maybe it should be a month for the bulls, not for turkeys.”\nWall Street avoids spooky October\nWhile October is often considered a spooky month for investors, earning a bad reputation following the crashes of 1929, 1987 and during the global financial crisis in 2008, investors weren’t so fearful this year.\nAfter the S&P 500 recorded its biggest monthly loss since the start of the coronavirus pandemic in September, the broad index rebounded more than 6% in October on further signs that corporate profits are growing once again following last year's recession.\n“It looks as though the market has resisted ‘Octoberphobia’ and averted the feared crashes or massacres that have given the month its bad reputation,” Jeff Hirsch, editor of the Stock Trader's Almanac, said in a note to clients.\nTo be sure, November has taken hits during bear markets, when major averages drop more than 20% from a recent peak.\nFor instance, November 2000 was the Nasdaq Composite’s second-worst month on record, with the technology-focused index plunging nearly 23%, according to the Stock Trader’s Almanac. Only October 1987 was worse, and that is when the \"Black Monday\" stock market crash occurred\nWhy investors should be optimistic\nThe U.S. economy slowed substantially from July through September following a series of obstacles, including a surge in COVID-19 cases, supply chain bottlenecks, rising consumer prices and the fading effects of federal stimulus measures.\nBut with COVID-19 cases now falling and vaccinations rising, most economists are branding the weak showing a soft patch in a still-robust recovery from the pandemic-induced recession, with a healthy rebound projected in the final months of the year.\nThere are signs that there could be more gains to come on Wall Street in the final months of the year on strong seasonality trends, better-than-expected corporate earnings and falling COVID-19 cases. Market breadth has also improved, meaning that more stocks are participating in the rally, a sign of a healthy and strong market.\nJobless claims have also fallen steadily in recent weeks, with continuing claims sliding below 2.5 million recently for the first time since the coronavirus pandemic began.\nAfter suffering its first 5% pullback of 2021 in early October, the S&P 500 has come roaring back and closed at a record high on October 21. The S&P 500 Index has gained more than 20% so far this year, making more than 50 record highs along the way.\nThat could be a positive sign for investors in the coming months. The past seven times the S&P 500 had risen 15% for the year heading into the fourth quarter, that final quarter ended up higher each time, rising 5.8%, data from LPL Financial showed.\n“We firmly believe that new highs are something to be embraced, not feared, and history shows that new highs tend to come in bunches—something that has certainly been true so far this year,” according to Detrick.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":631,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":820480770,"gmtCreate":1633415677663,"gmtModify":1633415677945,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/820480770","repostId":"2172968917","repostType":4,"isVote":1,"tweetType":1,"viewCount":293,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600311170,"gmtCreate":1638066328792,"gmtModify":1638066328908,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/600311170","repostId":"2186282013","repostType":4,"isVote":1,"tweetType":1,"viewCount":2185,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":814016110,"gmtCreate":1630727054930,"gmtModify":1631892030478,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/814016110","repostId":"1186003479","repostType":4,"isVote":1,"tweetType":1,"viewCount":320,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":811198035,"gmtCreate":1630294613627,"gmtModify":1704957977046,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Hood","listText":"Hood","text":"Hood","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/811198035","repostId":"2163776380","repostType":4,"isVote":1,"tweetType":1,"viewCount":684,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":600234330,"gmtCreate":1638155494839,"gmtModify":1638155494989,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/600234330","repostId":"1119853738","repostType":4,"repost":{"id":"1119853738","kind":"news","pubTimestamp":1638153494,"share":"https://www.laohu8.com/m/news/1119853738?lang=&edition=full","pubTime":"2021-11-29 10:38","market":"us","language":"en","title":"Moderna, Pfizer, and Novavax Are Must-Own Stocks This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1119853738","media":"Motley Fool","summary":"The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday","content":"<p>The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday. Omicron has the world on edge because of its unique combination of mutations that might significantly reduce the effectiveness of first-generation COVID-19 vaccines.</p>\n<p>While there simply isn't enough data to draw any firm conclusions about the seriousness of the omicron variant yet, politicians across the world were quick to react by imposing travel bans and restrictions on several African nations over the weekend. These rapid-fire travel restrictions make it abundantly clear that the global pandemic -- and its effects on the world economy -- are far from over.</p>\n<p>How should investors protect their portfolios from this latest threat to global supply chains, international travel, and public health? The answer appears to be simple enough: vaccine stocks. On Black Friday, shares of the top COVID-19 vaccine developers&nbsp;<b>Moderna</b>(NASDAQ:MRNA),<b>Pfizer</b>(NYSE:PFE), and&nbsp;<b>Novavax</b>(NASDAQ:NVAX)&nbsp;all&nbsp;vaulted higher. Here's why these threebiopharmaceutical stocksought to continue to their march northward next week and beyond.</p>\n<p>The pandemic's latest twist makes these three stocks screaming buys</p>\n<p>Moderna, Pfizer, and Novavax all enjoyed a sizable jump in their share prices during the holiday-shortened trading session on Friday thanks to their quick reaction to the omicron variant. Specifically, Moderna announced that it is working on an omicron-specific vaccine, as well a unique booster shot regimen, based on its currently authorized COVID-19 vaccine, that may provide a higher level of immune protection against this new variant.</p>\n<p>Pfizer, for its part, said that its&nbsp;<b>BioNTech</b>-partnered COVID-19 vaccine can easily be tailored to the omicron variant and be ready for use within 100-days -- that is, if the original version of its vaccine fails to provide adequate protection. Novavax also provided an update on its omicron vaccine strategy last Friday, with the biotech saying that it plans on having an omicron-specific shot ready for testing and manufacturing within the next few weeks.</p>\n<p>Why are these omicron-tailored vaccines a huge positive for their developers? The messenger RNA (mRNA) vaccines from Moderna and Pfizer/BioNTech both appeared to be on the back end of the commercial shelf lives prior to this news. As a result, Moderna's stock was in the midst of notable downward trend earlier this month. The sudden need for more potent booster shots and a potential variant-specific vaccine should keep Moderna's top line headed in the right direction in 2022, which ought to light a fire underneath the biotech's shares for the remainder of the year.</p>\n<p>While Pfizer's equity hasn't skipped a beat of late because of its oral coronavirus pill, the pharma giant now stands to possibly benefit from another year of exceptionally strong COVID-19 vaccine sales. Pfizer's stock, in turn, will probably continue to print ever-increasing record highs heading into 2022.</p>\n<p>On the Novavax side of ledger, the biotech's shares are currently down by a whopping 31% from their 52-week highs. The vaccine specialist's shares have&nbsp;dipped in the back half of 2021&nbsp;in response to manufacturing issues, regulatory delays, and a growing concern among investors that the company may have simply missed the boat.</p>\n<p>What's important to understand is that Novavax's COVID-19 vaccine is protein-based, which may appeal to a broad range of folks hesitant about cutting-edge mRNA vaccines. This new variant, therefore, ought to keep this latent demand for Novavax's alternative jab on the high side, as the company slowly completes the regulatory process in the all-important U.S. market.</p>\n<p>In short, Moderna, Pfizer, and Novavax are all poised to benefit in a big way from their unique vaccine development capabilities, making their stocks exceedingly strong buys this week.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, Pfizer, and Novavax Are Must-Own Stocks This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, Pfizer, and Novavax Are Must-Own Stocks This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-29 10:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/28/moderna-pfizer-and-novavax-are-must-own-stocks-thi/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday. Omicron has the world on edge because of its unique combination of mutations that might ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/28/moderna-pfizer-and-novavax-are-must-own-stocks-thi/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/11/28/moderna-pfizer-and-novavax-are-must-own-stocks-thi/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119853738","content_text":"The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday. Omicron has the world on edge because of its unique combination of mutations that might significantly reduce the effectiveness of first-generation COVID-19 vaccines.\nWhile there simply isn't enough data to draw any firm conclusions about the seriousness of the omicron variant yet, politicians across the world were quick to react by imposing travel bans and restrictions on several African nations over the weekend. These rapid-fire travel restrictions make it abundantly clear that the global pandemic -- and its effects on the world economy -- are far from over.\nHow should investors protect their portfolios from this latest threat to global supply chains, international travel, and public health? The answer appears to be simple enough: vaccine stocks. On Black Friday, shares of the top COVID-19 vaccine developers Moderna(NASDAQ:MRNA),Pfizer(NYSE:PFE), and Novavax(NASDAQ:NVAX) all vaulted higher. Here's why these threebiopharmaceutical stocksought to continue to their march northward next week and beyond.\nThe pandemic's latest twist makes these three stocks screaming buys\nModerna, Pfizer, and Novavax all enjoyed a sizable jump in their share prices during the holiday-shortened trading session on Friday thanks to their quick reaction to the omicron variant. Specifically, Moderna announced that it is working on an omicron-specific vaccine, as well a unique booster shot regimen, based on its currently authorized COVID-19 vaccine, that may provide a higher level of immune protection against this new variant.\nPfizer, for its part, said that its BioNTech-partnered COVID-19 vaccine can easily be tailored to the omicron variant and be ready for use within 100-days -- that is, if the original version of its vaccine fails to provide adequate protection. Novavax also provided an update on its omicron vaccine strategy last Friday, with the biotech saying that it plans on having an omicron-specific shot ready for testing and manufacturing within the next few weeks.\nWhy are these omicron-tailored vaccines a huge positive for their developers? The messenger RNA (mRNA) vaccines from Moderna and Pfizer/BioNTech both appeared to be on the back end of the commercial shelf lives prior to this news. As a result, Moderna's stock was in the midst of notable downward trend earlier this month. The sudden need for more potent booster shots and a potential variant-specific vaccine should keep Moderna's top line headed in the right direction in 2022, which ought to light a fire underneath the biotech's shares for the remainder of the year.\nWhile Pfizer's equity hasn't skipped a beat of late because of its oral coronavirus pill, the pharma giant now stands to possibly benefit from another year of exceptionally strong COVID-19 vaccine sales. Pfizer's stock, in turn, will probably continue to print ever-increasing record highs heading into 2022.\nOn the Novavax side of ledger, the biotech's shares are currently down by a whopping 31% from their 52-week highs. The vaccine specialist's shares have dipped in the back half of 2021 in response to manufacturing issues, regulatory delays, and a growing concern among investors that the company may have simply missed the boat.\nWhat's important to understand is that Novavax's COVID-19 vaccine is protein-based, which may appeal to a broad range of folks hesitant about cutting-edge mRNA vaccines. This new variant, therefore, ought to keep this latent demand for Novavax's alternative jab on the high side, as the company slowly completes the regulatory process in the all-important U.S. market.\nIn short, Moderna, Pfizer, and Novavax are all poised to benefit in a big way from their unique vaccine development capabilities, making their stocks exceedingly strong buys this week.","news_type":1,"symbols_score_info":{"MRNA":0.9,"NVAX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2088,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872565417,"gmtCreate":1637549083380,"gmtModify":1637549127663,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/872565417","repostId":"2185826127","repostType":4,"isVote":1,"tweetType":1,"viewCount":601,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848618867,"gmtCreate":1635994051024,"gmtModify":1635994181360,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/848618867","repostId":"2180636457","repostType":4,"isVote":1,"tweetType":1,"viewCount":545,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":858683109,"gmtCreate":1635044597255,"gmtModify":1635044597534,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/858683109","repostId":"1100055241","repostType":4,"isVote":1,"tweetType":1,"viewCount":466,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":882838620,"gmtCreate":1631672328560,"gmtModify":1631889928966,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/882838620","repostId":"1133388737","repostType":4,"isVote":1,"tweetType":1,"viewCount":413,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":881680595,"gmtCreate":1631330767917,"gmtModify":1631889928976,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Gkkd","listText":"Gkkd","text":"Gkkd","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/881680595","repostId":"1105074635","repostType":4,"isVote":1,"tweetType":1,"viewCount":404,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":812319484,"gmtCreate":1630552112848,"gmtModify":1631892030482,"author":{"id":"3582719067968878","authorId":"3582719067968878","name":"Nyannie","avatar":"https://static.tigerbbs.com/e49d49ced16baf68b59df813f08820a8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582719067968878","authorIdStr":"3582719067968878"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/812319484","repostId":"2164125738","repostType":4,"isVote":1,"tweetType":1,"viewCount":472,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}